Journal
STEM CELLS TRANSLATIONAL MEDICINE
Volume 10, Issue 11, Pages 1491-1499Publisher
OXFORD UNIV PRESS
DOI: 10.1002/sctm.21-0183
Keywords
COVID-19; human ES cells; human iPS cells; organoids; SARS-CoV-2
Categories
Ask authors/readers for more resources
Experimental cell models using human ES/iPS cell-derived somatic cells and organoids play a crucial role in understanding the pathophysiology of COVID-19 and developing therapeutic agents, by replicating SARS-CoV-2 infection and damage in various organs to evaluate antiviral efficacy and safety of potential treatments.
Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available